The GSK Supported Studies Portal is being upgraded and will be unavailable from Wednesday 27th of January at 5.00PM EST to Tuesday 2nd of February 7.00am EST . If you are anticipating submitting a proposal during this time please submit once the new system is live on the 2nd of February. During this time please contact your Country Medical Point of Contact for any queries. We apologise for any inconvenience.

The Supported Studies Programme

View All Selected

Clear All

For the latest updates on GSK’s response to COVID-19, please click here.

Global Health

Timelines

Within Global Health we specifically focus on diseases that predominantly affect low- and lower middle-income countries, with projects targeting infectious diseases such as malaria, tuberculosis, enteric diseases and neglected tropical diseases.

[For Tafenoquine - Last updated October 2022]
In Malaria our key areas of interest are

   •   Tafenoquine for radical cure of P. vivax malaria
   •   G6PD diagnostic and treatment with Tafenoquine in patients with P. vivax malaria.
   •   Use of Tafenoquine with Chloroquine
   •   Tafenoquine effectiveness in patients with P.vivax malaria.
   •   PK/PD study in patients with P.vivax malaria.
   •   Comparative study of Tafenoquine vs Primaquine.
   •   Healthcare resource use and direct cost to the healthcare system including
         o   the economic impact of labour force participation and absenteeism due to Vivax
         o   the economic impact of cure.

GSK are more likely to support studies aligned to our current areas of interest when they are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology. GSK Global Health encourages submissions throughout the year.